Nanologica AB

NICA

SE0005454873

Commodity Chemicals

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2025-07-11 pm EDT			5-day change	1st Jan Change
1.140 ^SEK	-3.39%		+2.70%	-37.36%

Jul. 10	Nanologica AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
Jul. 10	Nanologica Increases Revenue but Reports Wider Operating Loss	FW

Nanologica receives SEK 38,000 from the exercise of TO5 - the subscription price was below the market price

Published on 05/26/2025 at 00:48

Life science company Nanologica has concluded the redemption period for warrants of series TO5, where a total of 12,586 options were exercised, corresponding to approximately 0.1 percent of the total number. The company will thus receive approximately SEK 38,000 before issue costs.

The background is that the subscription price was SEK 3, which can be compared with the stock market price on Friday of SEK 1.09.

The exercise entails a dilution of approximately 0.014 percent.

Go to the original article.
Legal disclaimer

Latest news about Nanologica AB

Nanologica AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	Jul. 10	CI
Nanologica Increases Revenue but Reports Wider Operating Loss	Jul. 10	FW
Nanologica Q2 adjusted EPS SEK -0.14	Jul. 10	RE
Nanologica Board Recommends Not To Accept Cash Offer Made By Flerie Invest	Jun. 13	RE
Nanologica's board of directors advises against accepting Flerie's mandatory bid offer.	Jun. 13	FW
Nanologica's board of directors advises against accepting Flerie's bid	Jun. 13	FW
Nanologica Receives First U.S. Order	Jun. 12	CI
Nanologica Gets Order Of Appx. SEK 1.3 Mln	Jun. 12	RE
Nanologica receives order worth approximately SEK 1.3 million from new customer in the US	Jun. 12	FW
Nanologica AB Receives Order of Appx. SEK 1.3 Million from New Customer in the US	Jun. 12	CI
Nanologica receives SEK 38,000 from the exercise of TO5 - the subscription price was above the market price (R)	May. 26	FW
Nanologica receives SEK 38,000 from the exercise of TO5 - the subscription price was below the market price	May. 26	FW
Stockholm Bullets - Active Biotech climbs on positive study results	May. 23	FW
Flerie makes mandatory bid for Nanologica – offers SEK 1 per share	May. 23	FW
Flerie Invest AB proposed to acquire remaining 56.74% stake in Nanologica AB (OM:NICA) for SEK 50.1 million.	May. 22	CI
Nanologica AB Announces Board Resignations	May. 22	CI
Flerie triggers mandatory bid for Nanologica after further share acquisition	Apr. 28	FW
Redeye lowers motivated value for Nanologica to SEK 3.0 (3.5)	Apr. 24	FW
Nanologica Receives an Important Order from New Customer	Apr. 24	CI
Nanologica Wins Silica-based Purification Media Order from Chinese Customer	Apr. 23	MT
Nanologica receives order from new customer in China	Apr. 23	FW
Nanologica Receives Order Worth $180,000 In China	Apr. 23	RE
Nanologica AB Receives Order Worth USD 180,000 from New Customer in China	Apr. 23	CI
Stockholm Stock Exchange - Nordea report beats expectations	Apr. 16	FW
Nanologica increases turnover and reduces loss	Apr. 16	FW

Chart Nanologica AB

Duration

Period

NICA: Dynamic Chart

Company Profile

Nanologica AB (publ) is a Sweden-based materials development company. The Company specializes in developing nanoporous materials from nanoporous silica (silicon dioxide) for a variety of applications, ranging from purification to pharmaceutical excipients. The Company's core competency has been developed and expanded in two areas of application, in particular: Drug Delivery and Chromatography, a technology used for the separation and purification of products on the market and in development. The Company's Drug Delivery sector operates within a niche domain of nanocarriers. Nanologica AB (publ)âs drug delivery technology is aimed on absorption of the medicine by the body for drugs that are poorly soluble in water.

Employees

Sector

Commodity Chemicals

Calendar

Oct. 22 - Q3 2025 Earnings Release

More about the company